US OptionsDetailed Quotes
HUMA241018C5000
- 0.75
- +0.05+7.14%
15min DelayClose Oct 4 16:00 ET
0.76High0.60Low
0.70Open0.70Pre Close28 Volume1.39K Open Interest5.00Strike Price1.85KTurnover133.13%IV5.70%PremiumOct 18, 2024Expiry Date0.44Intrinsic Value100Multiplier13DDays to Expiry0.31Extrinsic Value100Contract SizeAmericanOptions Type0.6803Delta0.2620Gamma7.02Leverage Ratio-0.0196Theta0.0010Rho4.77Eff Leverage0.0037Vega
Humacyte Stock Discussion
Sign in to post a comment
$Humacyte (HUMA.US)$ What a heck was it? They did it agsin! only a moment of joy 😵💫
1
1
$Humacyte (HUMA.US)$ take profits to RR Richtech Robotics using a i Nvidia chip with a showing soon 🐂💥🚀📈
$Humacyte (HUMA.US)$
+20% today 😃
+20% today 😃
1
2
$Humacyte (HUMA.US)$ Reuters
1 min ago
Humacyte Announces Allowance of U.S. Patent Covering Biovascular Pancreas (Bvp™)
1 min ago
Humacyte Announces Allowance of U.S. Patent Covering Biovascular Pancreas (Bvp™)
1
$Humacyte (HUMA.US)$ I know the news hasn't been superb, can always be better...
but the chart looks very very good here..
looks like 9+++ is coming
the options are spread too far apart if they had a $6 strike I think that would make the most sense but they have a 7.50 and to buy it at 60 cents would give you an 8.10 cost basis.. and if we see 9.50 which I think would be like a best case scenario that would yield a 1.40 so I don't think I don't think the options are a good play here because the...
but the chart looks very very good here..
looks like 9+++ is coming
the options are spread too far apart if they had a $6 strike I think that would make the most sense but they have a 7.50 and to buy it at 60 cents would give you an 8.10 cost basis.. and if we see 9.50 which I think would be like a best case scenario that would yield a 1.40 so I don't think I don't think the options are a good play here because the...
5
1
$Humacyte (HUMA.US)$ Humacyte Reports Positive Results From ATEV Treatment of Vascular Trauma in Ukraine
MT Newswires· 5 mins ago
Humacyte (HUMA) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.
The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV wer...
MT Newswires· 5 mins ago
Humacyte (HUMA) on Tuesday reported positive long-term results from its humanitarian program in Ukraine using the investigational acellular tissue engineered vessel, or ATEV, to treat severe vascular injuries.
The long-term data from the V017 trial showed 87.1% primary and secondary patency at 12 months. No infections, amputations, or deaths related to the ATEV wer...
2
2
$Humacyte (HUMA.US)$ looks like government insiders wanted one more chance to get in first. someone bought that dip hard
1
Nasty drop AH. Here are the levels to watch when the dust settles.
Larger Image: tradingview.com...
$Humacyte (HUMA.US)$
Larger Image: tradingview.com...
$Humacyte (HUMA.US)$
1
$Humacyte (HUMA.US)$ should have sold when 50% profit now sold around breakeven wasted 23 days hard lesson , never overstaying again in anything 👍all holders
loading...
3
1
$Humacyte (HUMA.US)$
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
Humacyte (Nasdaq: HUMA) announced that the FDA requires additional time to review its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in vascular trauma treatment. The FDA granted Priority Review in February 2024 with a PDUFA date of August 10, 2024. Despite active en...
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
Humacyte (Nasdaq: HUMA) announced that the FDA requires additional time to review its Biologic License Application (BLA) for the acellular tissue engineered vessel (ATEV) in vascular trauma treatment. The FDA granted Priority Review in February 2024 with a PDUFA date of August 10, 2024. Despite active en...
5
No comment yet
10baggerbamm : the mkt is week and people are closing out positions in they had short term profits in .